Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR, Luciferase Reporter Assay |
| Sample | primary cervical cancer tissues, cell lines (HeLa, CaSki, SiHa, HT-3, and C33A) |
| Expression Pattern | up-regulated |
| Function Description | RT-PCR showed that ANRIL expression was significantly upregulated in cervical cancer tumors and cell lines. The bioinformatics prediction program and luciferase assay predicted and validated that miR-186 directly targeted ANRIL. The expression level of miR-186 was downregulated in cervical cancer tumors and cell lines and was negatively correlated to that of ANRIL. |
| Pubmed ID | 28550682 |
| Year | 2017 |
| Title | Long Noncoding RNA ANRIL Promotes Cervical Cancer Development by Acting as a Sponge of miR-186 |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |